Nemeth-Kellner Lymphoma Is a Valid Experimental Model in Testing Chemical Agents for Anti-Lymphoproliferative Activity*

DOI: 10.4236/ojbd.2013.33A001   PDF   HTML     2,359 Downloads   4,303 Views   Citations


Scheme of detection and investigation of antitumor activity of chemical substances by use of experimental murine Nemeth-Kellner lymphoma (NK/Ly) are described. It includes monitoring of growth of NK/Ly ascites by everyday weighting of animals in course of intraperitoneal application of tested substance in 24 or 48 hours after inoculation of 107 tumor cells. The inhibitory effect became distinct on the 6th-8th day of experiment, and 3 types of response were observed: 1) complete suppression of ascites development, corresponding to high antitumor activity of tested substance; 2) partial suppression of ascites growth (weak antitumor activity); 3) insignificant effect on ascites growth (lack of activity, at least towards hematoblastoses). As compared with leukemia L1210 or P388 lymphoma NK/Ly provides more distinct daily increment of body weight due to tumor growth. Clinical pattern of tumor development was supported by cytomorphological investigations of tumor cells which included: 1) cells count in ascites; 2) measuring cell dimensions and ratio of enlarged cells in a population (diameter over 17 μm in case of NK/Ly); 3) quantitative evaluation of tumor cells damage by smears count after staining with azure-eosin, bromophenol blue and hematoxylin. In case of complete suppression of ascites growth the cytological investigation was conducted by delayed application of tested agent to animals with the developed ascites. After treatment with vinblastine or doxorubicin NK/Ly cells represent a convenient object for fractionation of cell population, as demonstrated by separation of giant and small tumor cell subpopulations.

Share and Cite:

M. D. Lootsik, M. M. Lutsyk and R. S. Stoika, "Nemeth-Kellner Lymphoma Is a Valid Experimental Model in Testing Chemical Agents for Anti-Lymphoproliferative Activity*," Open Journal of Blood Diseases, Vol. 3 No. 3A, 2013, pp. 1-6. doi: 10.4236/ojbd.2013.33A001.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] L. Nemeth and B. Kellner, “A New Mouse Ascites Tumour to Be Used as a Screening Tool,” Neoplasma, Vol. 8, No. 4, 1961, pp. 337-343.
[2] L. Nemeth and F. Gal, “Growth of Three Mouse Ascites Tumours in Nine Different Strains,” Neoplasma, Vol. 11, No. 2, 1964, pp. 241-249.
[3] C. Sellei, S. Ekhardt and L. Nemeth, “Daganatos Betek Segek Gyogyszeres Keselese (Drug Treatment of Tumor Diseases),” Akademiai Kiado, Budapest, 1975, pp. 21-25.
[4] A. Kurnatowski and R. Willighagen, “Cytochemistry of the NK/Ly Lymphoma,” Nature, Vol. 193, No. 4886, 1963, pp. 91-92.
[5] E. Schauenstein, H. Zollner, M. Ernet and H. Esterbauer, “Experiments on the Therapeutic Effect of 4-Hydroxy- pen-Tenal. Inhibition of the Growth of Solid Nemeth- Kellner-Lymphoma,” Zeitschrift fur Krebsforschung und Klinische Onkologie, Vol. 76, No. 2, 1971, pp. 140-144.
[6] L. Kopper, A. Jeney, K. Lapis and M. Torok, “Studies of the Growth of an Ascitic Tumour. II A System to Study Tumour-Age Dependent Effect of Antitumour Agents,” European Journal of Cancer, Vol. 14, No. 1, 1978, pp. 75-82.
[7] L. Fiszer-Maliszewska, W. Peczyńska-Czoch, J. Wieczorek, M. Mordarski, R. Balicki and P. Nantka-Namirski, “Antineoplastic Activity of New Linear Hydrazine Derivatives,” Archivum Immunologiae et Therapiae Experimentalis, Vol. 35, No. 2, 1987, pp. 225-235.
[8] Z. Machoń, J. Wieczorek and M. Mordarski, “Isothiazolo-Pyrimidines—New Group of Anticancer Agents,” Archivum Immunologiae et Therapiae Experimentalis, Vol. 35, No. 5, 1987, pp. 599-607.
[9] G. G. Bratus’, O. P. Naumenko, E. P. Nastenko and O. I. Novichenko, “Morpho-Functional Characteristic of LY- MPH-OMA NK/Ly Cells Treated with Concanavalin A and Neura-Minidase of Vibrio cholerae,” Tsitologiya (Cytology), Vol. 32, No. 1, 1990, pp. 67-75.
[10] Z. P. Sofyina, A. B. Syrkin, A. Goldin and I. Klein, “Experimental Evaluation of Antitumor Substances in USSR and USA,” Medicine, Moscow, 1980, pp. 76-77.
[11] M. Lootsik, N. Boiko, M. Lutsyk and R. Stoika, “Purification of Sapogenin from Seeds of Greater Celandine (Chelidonium majus L.) and Investigation of Its Influence towards Experimental Lymphoma NK/Ly,” Proceedings of Shevchenko Scientific Society, Section of Chemistry and Biochemistry, Vol. 28, 2011, pp. 150-159.
[12] M. D. Lootsik, M. M. Lutsyk and R. S. Stoika, “Sapogenins Isolated from the Greater Celandine (Chelidonium majus) Seeds Potentiate a Therapeutic Effect of Vinblastine towards Murine NK/Ly Lymphoma,” Studia Biologica, Vol. 6, No. 3, 2012, pp. 29-38.
[13] P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. Mc-Mahon, D. Vishca, J. Warren, H. Bokesch, S. Xenney and M. Boyd, “Colorimetric Cytotoxicity Assay for Anti-Cancer Drug Screening,” Journal of the National Cancer Institute, Vol. 82, No. 13, 1990, pp. 1107-1112.
[14] M. M. Lutsyk and A. M. Yashchenko, “Quantitative Evaluation of Tumor Cells Damage Due to in Vivo Action of Antitumor Agents by Staining Cytological Smear for Protein,” Visnyk morfologiyi (Morphological Reports), Vol. 15, No. 1, 2009, pp. 188-192.
[15] V. Kaminsky, O. Kulachkovskyy and R. Stoika, “A Decisive Role of Mitochondria in Defining Rate and Intensity of Apoptosis Induction by Different Alkaloids,” Toxicology Letters, Vol. 177, No. 3, 2008, pp. 168-181.
[16] D. N. Wheatley, “Regrowth of Tumor Cells from Supposedly Terminal Giant Cells,” Oncology News, Vol. 1, No. 3, 2006, p. 3.
[17] J. Erenpreisa, K. Salmina, A. Huna, E. A. Kosmacek, M. S. Cragg, F. Ianzini and A. P. Anisimov, “Polyploid Tumor Cells Elicit Paradiploid Progeny through Deploidizing Divisions and Regulated Autophagic Degradation,” Cell Biology International, Vol. 35, No. 7, 2011, pp. 687-695.
[18] P. E. Puig, M. N. Guilly, A. Bouchot, N. Droin, D. Cathelin, F. Bouyer, L. Favier, F. Ghiringhelli, G. Kroemer, E. Solary, F. Martin and B. Chauffert, “Tumor Cells Can Escape DNA-Damaging Cisplatin through DNA Endoreduplication and Reversible Polyploidy,” Cell Biology International, Vol. 32, No. 9, 2008, pp. 1031-1043.
[19] J.-Y. Lin, K.-Y. Tserng, Ch. Chen, L.-T. Lin and T.-Ch. Tung, “Abrin and Ricin: New Anti-Tumor Sustances,” Nature, Vol. 227, No. 5255, 1970, pp. 292-293.
[20] M. D. Lutsik, “The Antitumour Activity of Phytohemagglutinin from Viscum album L.,” Reports of Academy of Sciences of Ukrainian SSR, Series B, No. 6, 1975, pp. 543-545.
[21] E. L. Prihozhina and E. L. Vendrov, “On a Necessity of Cytogenetic Control of Tumor Strains,” Voprosy Onkologii (Problems of Oncology), Vol. 17, No. 7, 1971, pp. 83-85.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.